Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Buprenorphine Stories

2014-04-15 16:28:26

SAN DIEGO, April 15, 2014 /PRNewswire/ -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the U.S. District Court in Massachusetts entered an order, preventing the implementation of the Commonwealth's ban of Zohydro(TM) ER on Constitutional grounds. This order will become effective on April 22, 2014. The court decision today supports the...

2014-04-09 23:03:38

Opiate abuse is growing quickly in the Tampa area. Millennium Treatment Group is seeing an influx of patients with an addiction to opiates and can offer a great treatment option to help the community. Lake Worth, FL (PRWEB) April 09, 2014 Opiate addiction is on the rise in the Tampa area. Millennium Treatment Group has seen a recent increase in the number of patients needing treatment. Because of this, Millennium Treatment Group is offering a great addiction treatment option for those in...

2014-04-09 08:28:50

Dr. Sarah Bagley to be honored at American Society of Addiction Medicine Conference SAN DIEGO and ORLANDO, Fla., April 9, 2014 /PRNewswire/ -- Millennium Research Institute (MRI) today announced Dr. Sarah Bagley, a fellow in addiction medicine in the Section of General Internal Medicine at Boston University Medical Center in Boston, as the inaugural recipient of the American Society of Addiction Medicine (ASAM) and Millennium Research Institute Research Fellowship Award, which...

2014-04-08 20:21:36

SAN DIEGO, April 8, 2014 /PRNewswire/ -- Today Zogenix presented its case in U.S. District Court in Boston requesting an immediate order staying the ban on the U.S. Food and Drug Administration (FDA)-approved prescription drug product, Zohydro(TM) ER (hydrocodone bitartrate) extended-release capsules (CII), entered on March 27, 2014, by Massachusetts Governor Deval Patrick. Zogenix appreciates the opportunity to be heard by the court on an expedited basis. A follow-up hearing has been...

2014-04-07 16:25:34

Company Files for Injunction - Prescription Drug Status Should Reside Solely With the FDA SAN DIEGO, April 7, 2014 /PRNewswire/ -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today filed a lawsuit in the U.S. District Court in Massachusetts requesting the court to grant a temporary restraining order against execution of the executive order recently announced by...

2014-04-07 12:32:56

First presentation of detailed BUNAVAIL clinical data scheduled for April 11 and 13, 2014 RALEIGH, N.C., April 7, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that data from clinical studies of BUNAVAIL will be presented at the American Society of Addiction Medicine (ASAM) 45(th) Annual Medical-Scientific Conference, April 10-13, 2014 in Orlando, Florida. Four abstracts will be presented highlighting data from the clinical development...

2014-04-07 08:30:13

RICHMOND, Va., April 7, 2014 /PRNewswire/ -- Kaleo (formerly Intelliject) today announced that it has entered into a $150 million debt facility with PDL BioPharma (NASDAQ: PDLI) to enable kaleo to support commercialization of EVZIO(TM)(naloxone hydrochloride injection) and development of key pipeline products. Under the financing, PDL provided $150 million in cash at closing and will receive interest on the principal outstanding. The note is backed by royalty payments on kaleo's first...

2014-04-03 12:29:15

First and only naloxone product specifically intended for emergency administration by family members or caregivers in settings where opioids may be present RICHMOND, Va., April 3, 2014 /PRNewswire/ -- Kaleo (formerly Intelliject) today announced that the U.S. Food and Drug Administration (FDA) has approved EVZIO(TM) (naloxone hydrochloride injection) for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. EVZIO...

2014-04-02 12:07:35

Researchers offer immediate steps to address rise in deaths There are important parallels between the early years of the HIV/AIDS epidemic and the current epidemic of opioid addiction - ones that could trigger a significant shift in opioid addiction prevention, diagnosis and treatment. These are the findings of a comparative review of HIV/AIDS and addiction by researchers Josiah D. Rich, M.D., M.P.H., director of the Center for Prisoner Health and Human Rights, based at The Miriam...

2014-03-27 08:33:37

Ashfield Market Access to provide managed markets and trade support RALEIGH, N.C., March 27, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), BDSI's proposed maintenance treatment for opioid dependence. BUNAVAIL is currently under review at the U.S. Food and Drug...